|
Gene: DDX5 |
Gene summary for DDX5 |
Gene summary. |
Gene information | Species | Human | Gene symbol | DDX5 | Gene ID | 1655 |
Gene name | DEAD-box helicase 5 | |
Gene Alias | G17P1 | |
Cytomap | 17q23.3 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P17844 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1655 | DDX5 | GSM4909277 | Human | Breast | Precancer | 6.04e-10 | 7.44e-01 | 0.0177 |
1655 | DDX5 | GSM4909286 | Human | Breast | IDC | 1.91e-06 | -7.89e-02 | 0.1081 |
1655 | DDX5 | GSM4909287 | Human | Breast | IDC | 4.57e-06 | 1.72e-01 | 0.2057 |
1655 | DDX5 | GSM4909289 | Human | Breast | IDC | 4.59e-06 | 4.77e-01 | 0.1064 |
1655 | DDX5 | GSM4909291 | Human | Breast | IDC | 7.05e-43 | 7.49e-01 | 0.1753 |
1655 | DDX5 | GSM4909293 | Human | Breast | IDC | 9.41e-48 | 6.21e-01 | 0.1581 |
1655 | DDX5 | GSM4909294 | Human | Breast | IDC | 2.69e-10 | -2.98e-01 | 0.2022 |
1655 | DDX5 | GSM4909295 | Human | Breast | IDC | 2.70e-07 | 3.95e-01 | 0.0898 |
1655 | DDX5 | GSM4909296 | Human | Breast | IDC | 2.05e-23 | -6.26e-01 | 0.1524 |
1655 | DDX5 | GSM4909297 | Human | Breast | IDC | 6.67e-32 | 2.93e-01 | 0.1517 |
1655 | DDX5 | GSM4909298 | Human | Breast | IDC | 4.01e-20 | 4.56e-01 | 0.1551 |
1655 | DDX5 | GSM4909299 | Human | Breast | IDC | 1.05e-13 | 4.13e-01 | 0.035 |
1655 | DDX5 | GSM4909300 | Human | Breast | IDC | 7.89e-04 | 3.67e-01 | 0.0334 |
1655 | DDX5 | GSM4909303 | Human | Breast | IDC | 8.83e-06 | 3.55e-01 | 0.0438 |
1655 | DDX5 | GSM4909305 | Human | Breast | IDC | 1.07e-04 | 2.89e-01 | 0.0436 |
1655 | DDX5 | GSM4909308 | Human | Breast | IDC | 1.11e-09 | 3.34e-01 | 0.158 |
1655 | DDX5 | GSM4909309 | Human | Breast | IDC | 2.01e-02 | 1.52e-01 | 0.0483 |
1655 | DDX5 | GSM4909311 | Human | Breast | IDC | 7.49e-41 | -4.51e-01 | 0.1534 |
1655 | DDX5 | GSM4909312 | Human | Breast | IDC | 2.41e-11 | -2.73e-01 | 0.1552 |
1655 | DDX5 | GSM4909313 | Human | Breast | IDC | 4.24e-03 | 1.64e-01 | 0.0391 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0034655111 | Skin | cSCC | nucleobase-containing compound catabolic process | 172/4864 | 407/18723 | 4.11e-13 | 2.43e-11 | 172 |
GO:007233129 | Skin | cSCC | signal transduction by p53 class mediator | 83/4864 | 163/18723 | 7.71e-12 | 4.00e-10 | 83 |
GO:0046700110 | Skin | cSCC | heterocycle catabolic process | 178/4864 | 445/18723 | 4.45e-11 | 2.13e-09 | 178 |
GO:000961522 | Skin | cSCC | response to virus | 152/4864 | 367/18723 | 5.88e-11 | 2.75e-09 | 152 |
GO:0044270110 | Skin | cSCC | cellular nitrogen compound catabolic process | 179/4864 | 451/18723 | 8.34e-11 | 3.79e-09 | 179 |
GO:0000380110 | Skin | cSCC | alternative mRNA splicing, via spliceosome | 47/4864 | 77/18723 | 9.03e-11 | 4.04e-09 | 47 |
GO:0019439110 | Skin | cSCC | aromatic compound catabolic process | 183/4864 | 467/18723 | 1.76e-10 | 7.68e-09 | 183 |
GO:0000956110 | Skin | cSCC | nuclear-transcribed mRNA catabolic process | 59/4864 | 112/18723 | 1.46e-09 | 5.60e-08 | 59 |
GO:1901361110 | Skin | cSCC | organic cyclic compound catabolic process | 188/4864 | 495/18723 | 1.92e-09 | 7.01e-08 | 188 |
GO:0050792112 | Skin | cSCC | regulation of viral process | 77/4864 | 164/18723 | 5.38e-09 | 1.78e-07 | 77 |
GO:004854529 | Skin | cSCC | response to steroid hormone | 135/4864 | 339/18723 | 1.34e-08 | 4.09e-07 | 135 |
GO:007233228 | Skin | cSCC | intrinsic apoptotic signaling pathway by p53 class mediator | 43/4864 | 76/18723 | 1.48e-08 | 4.49e-07 | 43 |
GO:0045069111 | Skin | cSCC | regulation of viral genome replication | 46/4864 | 85/18723 | 3.08e-08 | 8.30e-07 | 46 |
GO:190179629 | Skin | cSCC | regulation of signal transduction by p53 class mediator | 49/4864 | 93/18723 | 3.49e-08 | 9.19e-07 | 49 |
GO:003052227 | Skin | cSCC | intracellular receptor signaling pathway | 108/4864 | 265/18723 | 9.21e-08 | 2.21e-06 | 108 |
GO:1903900112 | Skin | cSCC | regulation of viral life cycle | 68/4864 | 148/18723 | 1.17e-07 | 2.77e-06 | 68 |
GO:00516076 | Skin | cSCC | defense response to virus | 107/4864 | 265/18723 | 1.84e-07 | 4.02e-06 | 107 |
GO:01405466 | Skin | cSCC | defense response to symbiont | 107/4864 | 265/18723 | 1.84e-07 | 4.02e-06 | 107 |
GO:0030518110 | Skin | cSCC | intracellular steroid hormone receptor signaling pathway | 56/4864 | 116/18723 | 1.97e-07 | 4.28e-06 | 56 |
GO:0071383111 | Skin | cSCC | cellular response to steroid hormone stimulus | 84/4864 | 204/18723 | 1.44e-06 | 2.48e-05 | 84 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520523 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
hsa0304023 | Breast | IDC | Spliceosome | 40/867 | 217/8465 | 1.53e-04 | 1.42e-03 | 1.06e-03 | 40 |
hsa0520533 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
hsa0304033 | Breast | IDC | Spliceosome | 40/867 | 217/8465 | 1.53e-04 | 1.42e-03 | 1.06e-03 | 40 |
hsa0520542 | Breast | DCIS | Proteoglycans in cancer | 39/846 | 205/8465 | 5.36e-05 | 5.58e-04 | 4.11e-04 | 39 |
hsa0304043 | Breast | DCIS | Spliceosome | 40/846 | 217/8465 | 8.97e-05 | 8.52e-04 | 6.28e-04 | 40 |
hsa0520552 | Breast | DCIS | Proteoglycans in cancer | 39/846 | 205/8465 | 5.36e-05 | 5.58e-04 | 4.11e-04 | 39 |
hsa0304053 | Breast | DCIS | Spliceosome | 40/846 | 217/8465 | 8.97e-05 | 8.52e-04 | 6.28e-04 | 40 |
hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0520517 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa05205 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
hsa03040 | Colorectum | AD | Spliceosome | 73/2092 | 217/8465 | 1.73e-03 | 9.68e-03 | 6.18e-03 | 73 |
hsa052051 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
hsa030401 | Colorectum | AD | Spliceosome | 73/2092 | 217/8465 | 1.73e-03 | 9.68e-03 | 6.18e-03 | 73 |
hsa052052 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
hsa052053 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
hsa052054 | Colorectum | MSS | Proteoglycans in cancer | 65/1875 | 205/8465 | 8.66e-04 | 5.38e-03 | 3.29e-03 | 65 |
hsa030402 | Colorectum | MSS | Spliceosome | 66/1875 | 217/8465 | 2.58e-03 | 1.27e-02 | 7.81e-03 | 66 |
hsa052055 | Colorectum | MSS | Proteoglycans in cancer | 65/1875 | 205/8465 | 8.66e-04 | 5.38e-03 | 3.29e-03 | 65 |
hsa030403 | Colorectum | MSS | Spliceosome | 66/1875 | 217/8465 | 2.58e-03 | 1.27e-02 | 7.81e-03 | 66 |
Page: 1 2 3 4 5 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DDX5 | SNV | Missense_Mutation | novel | c.778N>A | p.Pro260Thr | p.P260T | P17844 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AR-A2LL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
DDX5 | SNV | Missense_Mutation | novel | c.197N>G | p.Ala66Gly | p.A66G | P17844 | protein_coding | tolerated(0.08) | benign(0.027) | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
DDX5 | SNV | Missense_Mutation | novel | c.991N>T | p.Arg331Cys | p.R331C | P17844 | protein_coding | deleterious(0.01) | benign(0.046) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
DDX5 | SNV | Missense_Mutation | c.1379N>G | p.Leu460Arg | p.L460R | P17844 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BH-A1FC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
DDX5 | SNV | Missense_Mutation | c.214G>A | p.Glu72Lys | p.E72K | P17844 | protein_coding | deleterious(0) | possibly_damaging(0.662) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
DDX5 | insertion | Frame_Shift_Ins | novel | c.766dupA | p.Met256AsnfsTer4 | p.M256Nfs*4 | P17844 | protein_coding | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | ||
DDX5 | insertion | Nonsense_Mutation | novel | c.1032_1033insTTGAATGTGAAAACTTAAGCTGAAAAATTGT | p.Ile345LeufsTer6 | p.I345Lfs*6 | P17844 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
DDX5 | deletion | Frame_Shift_Del | rs782756724 | c.1620delC | p.Tyr540Ter | p.Y540* | P17844 | protein_coding | TCGA-BH-A0BM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
DDX5 | deletion | Frame_Shift_Del | novel | c.1030delA | p.Thr344ProfsTer18 | p.T344Pfs*18 | P17844 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
DDX5 | SNV | Missense_Mutation | rs781795658 | c.992N>A | p.Arg331His | p.R331H | P17844 | protein_coding | deleterious(0.05) | benign(0.133) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1655 | DDX5 | CLINICALLY ACTIONABLE | RX-5902 |
Page: 1 |